Sign in Subscribe
Cancer

Improved Outcomes with Matched Unrelated Donor Hematopoietic Cell Transplantation

Strategic Insights

— 1 min read

Investigators at the University of Texas MD Anderson Cancer Center have published a report comparing the outcomes of matched unrelated donor (MUD) and haploidentical donor hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis. The study, which included 5,873 adult patients who received MUD (n=1,973) or haploidentical (n=3,900) HCT with PTCy for acute leukemia or myelodysplastic syndrome between 2017 and 2021, found that MUD HCT was associated with improved overall survival (OS) and GVHD-free, relapse-free survival (GRFS) compared to haplo HCT.

Key Takeaways:

  • The study analyzed 5,873 adult patients who received MUD (n=1,973) or haploidentical (n=3,900) HCT with PTCy for acute leukemia or myelodysplastic syndrome between 2017 and 2021.
  • MUD HCT had improved three-year OS (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.76-0.95, p=0.003) and GRFS (HR 0.83, 95% CI 0.74-0.93, p=0.001) compared to haplo HCT.
  • The study found that haploidentical HCT had worse OS (HR 1.15, 95% CI 1.04-1.27, p=0.005) and GRFS (HR 1.19, 95% CI 1.10-1.29, p=0.001) compared to MUD HCT.
  • The research concluded that MUD HCT with PTCy-based GVHD prophylaxis is associated with improved outcomes compared to haplo HCT in adults with acute leukemia or MDS.

Statistics:

  • 5,873 patients were included in the study.
  • 1,973 patients received MUD HCT with PTCy.
  • 3,900 patients received haploidentical HCT with PTCy.
  • The study found a hazard ratio (HR) of 0.85 for three-year OS in favor of MUD HCT.
  • The study found a hazard ratio (HR) of 0.83 for three-year GRFS in favor of MUD HCT.

Sources:

  • NewsRx. New Findings from University of Texas MD Anderson Cancer Center in the Area of Stem Cell Transplants Described (Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide). Hematology Week. October 20, 2025; p 1032.
  • Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Blood Advances, 2025.
  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Read more